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AbsTRACT
Objective: The objective was to establish a pattern of tumor growth 
of the C6 model of glioblastoma multiform in Wistar rats via magnetic 
resonance imaging (MRI) for the subsequent verification of tumor 
volume reduction due to magnetic hyperthermia therapy. Methods: 
Young male Wistar rats weighing between 250 and 300 g were 
used for the C6 model. After the rates were anesthetized (55 mg/
kg ketamine and 11 mg/kg xylazine), C6 lineage tumorigenic cells 
suspended in culture medium (105 cells in 10 µl) were stereotaxically 
injected into the right frontal cortex (bregma coordinates: 2.0 mm 
anteroposterior, 3.0 mm laterolateral, and 2.5 mm depth) of the rats 
using a Hamilton syringe. For the control group, the rats were injected 
with culture medium without cells. MRI scans were performed at 14, 
21, and 28 d after the injection using a 2.0 T MRI scanner (Bruker 
BioSpec, Germany). The animals were anesthetized with 55 mg/kg 
ketamine and 11 mg/kg xylazine before being examined. Coronal 
multilayers were acquired using a standard spin echo sequence with 
the following parameters: repetition/echo time = 4.000 ms/67.1 ms, 
field of view = 3.50, matrix = 192, slice thickness = 0.4 mm, and 
slice separation = 0 mm. Results: The MRI analysis enabled a clear 
visualization of the tumor mass, and it was possible to establish the 
tumor volume parameters on the various days that were examined. 
The volume at 14 d after induction was 13.7 ± 2.5 mm3. On days 
21 and 28, the tumor volumes were 31.7 ± 6.5 mm3 and 122.1 
± 11.8 mm3, respectively. Conclusion: These results demonstrated 
that it is possible to evaluate the C6 model tumor volume in rats, 
which will allow for the future implementation and verification of 
magnetic hyperthermia therapy.
Keywords: Magnetic resonance imaging; Glioblastoma/therapy; Brain 
neoplasms; Rats, Wistar 
REsUMO
Objetivo: Estabelecer um padrão de crescimento tumoral (volume) 
em ratos Wistar submetidos ao modelo C6 de glioblastoma 
multiforme por meio de imagens de ressonância magnética para 
posterior verificação de redução de volume tumoral com a terapia 
de magnetohipertermia. Métodos: Para o modelo C6, utilizamos 
ratos Wistar, machos, jovens, pesando entre 250 e 300 g. Após 
anestesiados (cetamina 55 mg/kg e xilazina 11 mg/kg) foram 
injetadas estereotaxicamente células tumorigênicas linhagem C6 
suspensas em meio de cultura (105 células em 10 µL) no córtex frontal 
direito (coordenadas a partir do bregma: anteroposterior = 2,0 mm; 
látero-lateral = 3,0 mm; profundidade = 2,5 mm) com uma seringa 
Hamilton. No Grupo Controle, houve a injeção do meio de cultura sem 
as células. Posteriormente, foram feitas imagens mediante a técnica 
de imagem por ressonância magnética em 14, 21 e 28 dias após 
a injeção em um escâner de imagem por ressonância magnética 
2.0 T (Bruker BioSpec, Germany). Para o exame, os animais foram 
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anestesiados com cetamina 55 mg/kg e xilazina 11 mg/kg. Multifatias 
coronais foram adquiridas utilizando uma sequência spin-echo padrão 
com os seguintes parâmetros: TR/TE = 4,000 ms/67,1 ms, FOV = 3,50, 
Matrix 192, slice thickness = 0,4 mm e slice separation = 0 mm. 
Resultados: A análise das imagens de ressonância magnética do 
tumor possibilitou a clara visualização da massa tumoral, sendo 
possível ainda estabelecer parâmetros de volume tumoral nos 
diferentes dias analisados. O volume de 14 dias após a indução do foi 
de 13,7 ± 2,5 mm3. Aos 21 dias, o volume alcançado foi de 31,7 ± 
6,5 mm3 e, aos 28 dias, a massa tumoral atingiu 122,1 ± 11,8 mm3. 
Conclusão: Estes resultados mostraram a possiblidade de avaliação 
do volume tumoral no modelo C6 em ratos, o que possibilitará, no 
futuro, a aplicação da terapia de magnetohipertermia bem como 
verificação de seus resultados.
Descritores: Imagem por ressonância magnética; Glioblastoma/terapia; 
Neoplasias encefálicas; Ratos Wistar
INTRODUCTION
Gliomas are neuroepithelial tumors that originate in 
glial cells and correspond to 31% of primary tumors 
and 80% of malignant tumors of the central nervous 
system (CNS). Astrocytomas correspond to 76% of all 
gliomas, and glioblastomas represent 53.7% of these 
cases(1). Glioblastoma multiform (GBM) is the most 
common and malignant astrocytoma, and despite 
numerous advances in the diagnosis and treatment of 
these tumors, the prognosis for GBM remains limited 
with a life expectancy of less than 1 year(2,3). Thus, it 
is extremely important to search for new therapeutic 
approaches that provide a better quality of life for brain 
cancer patients.
Accordingly, several therapies for gliomas have 
been proposed, such as chemotherapy and radiotherapy 
strategies(4). In recent decades, thermotherapy has 
been used in combination with these therapies. 
Thermotherapy involves increasing with tumor 
temperature (43 to 47°C) with the intent of destroying 
the tumor cells(5-9). Recent studies have shown that 
hyperthermia can be induced in a localized manner 
by applying magnetic nanoparticles that heat the 
tumor region under an alternating magnetic field. 
This therapy, called magnetic hyperthermia (MHT), 
has shown good results in preclinical(10) and clinical(11) 
studies.
However, the search for new therapies requires 
the use of animal models that can mimic disease 
progression in humans. Currently, several animal 
models have been proposed, most of which utilize rats 
and mice(12,13).
A rat model of the Wistar strain, called C6, has 
been widely used in recent decades and has shown 
good applicability(14-19). Benda et al.(20) developed this 
model and found that they were able to develop brain 
tumors in Wistar rats after multiple injections of 
N-methylnitrosourea over approximately 8 months. 
The tumorigenic cells were cultured, and the lineage 
was developed from the sixth clone (C6). These tumors 
had a glial origin and characteristics similar to GBM 
development, thus displaying similar growth and 
invasion to that found in human tumors(21). Although 
the C6 model is a widely used for studies of tumor 
progression, the published patterns of growth show a 
large variability. To implement MHT, as well as other 
therapies, it is of paramount importance that we obtain 
these tumor progression parameters.
ObJECTIVEs
To establish the tumor growth pattern (volume) of C6 
GBM model Wistar rats using MRI and to verify the 
reduction of tumor volume due to MHT.
METHODs
Animals
This work was developed in accordance with the 
standards of the Hospital Israelita Albert Einstein 
(HIAE) Ethics in Animal Research Committee (Comitê 
de Ética em Pesquisa Animal do Hospital Israelita 
Albert Einstein). For all procedures, care was taken to 
minimize the number of animals used as well as their 
amount of suffering and stress.
For the C6 model, 2-month-old male Wistar rats 
weighing between 250 and 300g were used. The animals 
were housed in the vivarium of the Experimentation and 
Surgery Training Center (Centro de Experimentação e 
Treinamento em Cirurgia, CETEC) of the HIAE Brain 
Institute (Instituto do Cérebro, InCe) in individual 
polypropylene cages that were lined with autoclaved 
sawdust. They were provided with feed and water ad 
libitum via stainless steel cover grids with divisions for 
balanced feed and water. This vivarium is accredited 
by the International Association for Assessment and 
Accreditation of Laboratory Animal Care (AAALAC). 
The environment followed a 12 hour light/dark cycle 
(7 am to 7 pm) and was maintained at a constant 
temperature (21 ± 2°C) according to international 
specifications.
For the MRI, the animals were transported to the 
Magnetic Resonance Imaging and in vivo Magnetic 
Resonance Spectroscopy Center for the Study of Animal 
Models (Centro de Imagens e Espectroscopia in vivo 
por Ressonância Magnética para Estudo de Modelos 
Animais, CIERMag) of the Universidade de São Paulo 
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Institute of Physics, São Carlos, where they were 
housed in the vivarium under the same aforementioned 
conditions until the final phase of the experiments.
C6 glioma cell culture
The C6 glioma cells of the Wistar rats were grown at 
37ºC (5% CO2) in Dulbecco’s Eagle medium (Gibco, 
Gaithersburg, MD) that contained 20% fetal bovine 
serum (Invitrogen). At 90% cell confluence, the 
medium was removed, and the cells were released 
for incubation using trypsin (0.04% of trypsin/
EDTA). The cells were centrifuged at 800 rpm for 
5 min, resuspended in Dulbecco’s medium at a final 
concentration of 105 cells/10 µL, and kept cool until 
implanted.
stereotaxic implantation of C6 cells 
The animals were anesthetized with ketamine (55 mg/
kg) and xylazine (11 mg/kg). to implant the C6 cells. 
The hair was then removed from the top of the head. 
The animal was fixed to the stereotaxic apparatus 
(Stoelting®, model 51700) using in-ear and upper teeth 
bars. After making a skin incision on the dorsal region 
of the skull and removing the periosteum, a trepanation 
of the bone cap was made using a dental drill. The 
implantation position was determined and marked 
on the bone according to Swanson’s Stereotaxic Atlas 
guidelines (1992) at the following coordinates: 2.0 mm 
anteroposterior, 2.0 mm laterolateral, and a depth of 
2.5 mm. A Hamilton syringe was used to implant 105 
tumorigenic glioma cells in 10 µL of culture medium 
cells into the right frontal cortex. The cells were slowly 
injected over a 10 min period. For the control group, 
culture medium was injected without the cells. The 
syringe was kept in position for an additional 2 min 
before being withdrawn. To avoid drawing the injected 
solution back into the needle, the syringe was slowly 
raised until it was completely removed from the brain. 
The bone was then reassembled using bone wax, and 
the skin was sutured using cotton thread.
MRI tumor analysis 
Prior to each imaging session, the animals were 
anesthetized using a mixture of ketamine (95 mg/kg) and 
xylazine (12 mg/kg). The animals were then placed in a 
ventral decubitus position on a soft, absorbent surface. 
After positioning the head inside the coil, the head 
was fixed using the ear and nasal bars, and the set was 
shielded. Finally, this entire set assembly was introduced 
to the magnet, which had a 150 mm internal diameter.
The magnetic resonance images were acquired using 
a horizontal superconducting magnet from Oxford 
Instruments (2 T field; model 65310HR) that operated 
in conjunction with a Bruker® spectrometer. The rapid 
acquisition with relaxation enhancement (RARE) 
sequence was used to acquire T2 weighted images with 
the following parameters: repetition time = 4.000 ms, 
echo time = 67.1, RARE factor = 6, means = 18, 
and bandwidth = 12.5 KHz. The acquisition time was 
approximately 50 min per animal. The field of view 
was 35x35 mm3 with an array of 192x192 points to 
produce a spatial resolution of 182x182 µm. A total 
of 26 slices were used at a 0.5 mm thickness without 
spacing between the slices. 
For the 26 total slices taken during each imaging 
session, the slices for which the tumor was visible were 
selected, and regions of interest were drawn using 
Paravision 5® software. The tumor area was identified 
for each slice and then summed and multiplied by the 
slice thickness to obtain the tumor volume.
Histopathological analysis of tumor tissues
After image acquisition, the animals were anesthetized 
and transcardially perfused with a buffered saline 
solution and 4% paraformaldehyde (PFA). The brains 
were removed and stored in PFA for 24 hours; they 
were then cryoprotected in a 40% sucrose solution for 
48 hours. Subsequently, 40 µm thickness coronal 
sections were cut using a cryostat (Leica) and stained 
via the standard hematoxylin-eosin technique.
REsULTs
MRI analysis of tumor volumes 
The progression of tumor growth of the C6 model was 
monitored using MRI (Figure 1). In the controls that 
were injected with culture medium only, the presence of 
tumor tissues was not detected over the 28-day period 
(Figure 1A).
On day 14, a tumor mass was observed (tumor + 
edema + necrotic area) that had a well-defined circular 
shape compared to the adjacent brain tissue, and thus, 
it was possible to outline the mass due to the intense 
signal in the affected region. The calculated volume on 
day 14 was 13.7 ± 2.5 mm3 (Figure 1B). On day 21, the 
tumor was clearly demarcated, with a volume of 31.7 
± 6.5 mm3, and it began to cause compression of the 
right ventricular region (Figure 1C). On day 28, the 
tumor growth reached 122.1 ± 11.8 mm3 (Figure 1D). 
After 28 days, the animals were sacrificed, and their 
brains were removed for later analysis.
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Figure 1. MRI follow-up of tumor progression in the C6 model. The images show sequences of brain slices for which it was possible to observe the tumor.  
(A) No tumor growth was observed for the brains in which only culture medium was injected. The arrow superficial to the cortex indicates the region where the  
syringe was inserted. (B) After 14 d, it was possible to observe an intense signal in the region inoculated with tumorigenic cells, and the tumor volume reached  
13.7 ± 2.5 mm3. (C) On day 21, a well-defined circular tumor that measured 31.7±6.5 mm3 was evident. (D) On day 28 after inoculation, a large tumor with a 
calculated mass of 122.1±11.8 mm3 was observed; this tumor began to compress the ventricular region
A
b
C
D
Figure 2. Histopathological characteristics of the C6 model. (A) A histological 
section and (B) an MRI image showing the circular tumor “T” clearly outlined and 
compressing ventricular structures. (C) N, necrosis area, and P, pseudopalisade, 
cells adjacent to the necrosis area. (D) The edge of the tumor and the presence  
of giant cells (arrow) and CN, normal brain tissue. Magnification: (A) x10, (B) 
x10, (C) x100, and (D) x400
A
C
b
D
Histopathological analysis
The histopathological evaluation of the gliomas 
implanted in the Wistar rats is presented in figure 2. 
The tumors presented GBM characteristics that were 
consistent with those previously demonstrated by 
Morrone et al.(22). Figure 2 shows a histological section 
(Figure 2A) and an MRI (Figure 2B) of a glioblastoma 
tumor. In accordance with the GBM characteristics, 
necrotic lesions, pseudopalisade-type atypical cells 
(Figure 2C), giant cells (Figure 2D), and hemorrhagic 
areas are highlighted.
DIsCUssION
GBM is a highly aggressive primary tumor of the CNS, 
and the average survival time of patients with GBM 
does not exceed 15 months of diagnosis, regardless of 
all available therapies(4,23). Thus, attempts to develop 
new therapies are of extreme importance. MHT has 
been used in combination with existing therapies and 
has provided favorable results(11). Studies conducted 
since the 1990s have shown that the use of magnetic 
nanoparticles is extremely efficient in generating 
heat after the application of a magnetic field, and 
this heat is capable of destroying cancer cells of the 
nervous system(24). In addition, the recent work of Van 
Landeghem et al.(25) in humans showed the ability of 
MHT to increase the life expectancy of GBM patients.
The C6 model features histopathological 
characteristics, such as the presence of pseudopalisade 
cells, necrotic areas, and microvascular proliferation, 
that are comparable to those found in GBM patients(26). 
The present study confirmed these characteristics, which 
supports this model as a useful tool for the development 
of new therapies, such as MHT. However, for the 
assessment of MHT, monitoring tumor development 
is essential because the objective of MHT is to reduce 
tumor volume. MRI allows for the follow-up of tumor 
volume as well as modifications and deformations of 
surrounding regions(27). In the present study, the rapid 
growth of a tumor mass using MRI was evaluated. The 
15Tumor growth analysis by magnetic resonance imaging of the C6 glioblastoma model
einstein. 2012;10(1):11-5
tumors progressed and compressed the ventricular 
region along the rostro-caudal axis. Tumor volumes in 
rats, which were measured 20 d after the implantation 
of cancer cells and analyzed in vivo by MRI, were similar 
to the volumes found in histological studies performed 
by Morrone et al.(22). This finding demonstrates that 
tumor measurement using imaging techniques can 
generate reliable data on the magnitude of tumors in 
vivo and can provide information regarding other brain 
structures that may be compressed are compromised. 
MRI data also permit the correlation analyses of 
behavioral and histological data that are acquired from 
the same animal.
CONCLUsION
The MRI analysis enabled the clear visualization of 
tumor mass and growth, which allowed tumor volume 
parameters of the C6 model to be analyzed on various 
days. The results obtained here are important for future 
applications of the MHT technique because tumor 
growth progression is directly related to the power of 
the magnetic field and the duration of the therapy that 
is applied.
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